The collaboration will focus on various aspects of the human microbiome that could benefit new product development.
Depressed BD patients present significant alterations in the taxonomic compositions of their gut microbiota, and this may be related to inflammatory pathways and depression severity.
Elisabetta Caselli, University of Ferrara (Italy), talks about a new and innovative use of probiotics to modulate the "hospital microbiome” in order to reduce the use of chemical disinfectants.
George Paraskevakos, Executive Director at International Probiotics Association, talks about probiotic and live biotherapeutic products market evolution and perspective.
The findings of a recent study suggest that a mild gastrointestinal infection can alter gut commensal populations in ways that boost the commensal’s ability to proliferate during an infection.
The findings of a recent study imply that Fusobacterium nucleatum may play a causal role in worsening RA, offering potential therapeutic targets for effectively alleviating RA symptoms.
The highlights of the Postbiotics Discussion Panel that took place in Bratislava during IPC 2023.
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis.
Philippe Langella, Research Director at the French National Institute of Agricultural Research, discussed the potential of Faecalibacterium Prausnitzii as Live Biotherapeutics for several disease.
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x.
